Popular Articles
Cellulite Cream

Group Health Cooperative Shows Investing In More Primary Care Pays For Itself
An evaluation of recent innovations in delivering primary care at a Group Health Cooperative medical center shows significant success and rapid return on investment. The data led to a decision to invest in these best practices in all of Group Health"s 26 medical centers by 2010.
generic viagra online
Ad Update: Religious Groups Back Reform, Unions Target Senators' Tax Plans
"Labor unions are showing their increasing displeasure over [health reform] financing proposals that target their healthcare benefits by launching attack ads against key lawmakers, causing the Senate"s leading advocate of taxing such benefits to seek an end to one especially aggressive campaign," Congress Daily reports. The Laborers" International Union of North America pulled an ad in Montana attacking Senate Finance Committee Chairman Max Baucus at the senator"s request, and after he asked to meet with the union"s president to discuss proposals (Dann, 6/30).
News of the day
Blacks More Likely To Die Of Ovarian, Breast Cancer When Receiving Same Treatment As Whites
Blacks receiving treatment equal to whites are more likely to die of breast, prostate and ovarian cancers but not many other types of cancer, according to a study published online Wednesday in the Journal of the National Cancer Institute, the Washington Post reports. Previous research has found that lower survival rates for many diseases, including cancer, among low-income populations and minorities often can be attributed to inferior care. These groups are less likely to have insurance and receive routine preventive care, and they are more likely to be diagnosed later and receive less aggressive treatment, research has shown. The new study is the first "that offers provocative evidence" to suggest that biological factors play a role in at least some racial disparities, according to the Post.For the study, Kathy Albain of Loyola University and colleagues examined data collected on nearly 20,000 patients between 1974 and 2001 by the Southwest Oncology Group, a national cooperative of NCI-funded clinical trials. Because all participants received the same care, if socioeconomic factors were affecting survival rates, then differences in those rates would remain constant across all forms of cancer, the researchers reasoned. An analysis of the data found no statistically significant association between race and survival for lung cancer, colon cancer, leukemia, lymphoma or myeloma. However, blacks were 49% more likely than whites to die from early stage postmenopausal breast cancer, 41% more likely to die from early stage premenopausal breast cancer, 61% more likely to die from advanced ovarian cancer and 21% more likely to die from advanced prostate cancer.Albain said, "When there"s a level playing field with the same quality of care, African-Americans survive just as well as other races from some of our most common cancers, which is reassuring news and points us nationally toward a need to make sure there is quality of care and equal access to all." She added that "for prostate, ovarian and breast (cancer), it"s not access to care. There"s something else. And we need to sort that out." Although some of the difference in breast cancer survival rates could be explained by a higher likelihood of black women developing a more aggressive form of the disease, Albain said that this factor could not account for the entire difference in survival rates. Albain also said that because all the cancers with persisting disparities were gender-specific, the gap in survival rates "is almost certainly related to a mix of factors across races pertaining to tumor biology and inherited factors," such as genes that control metabolism of drugs and hormones.However, American Cancer Society Chief Medical Director Otis Brawley said that access to adequate care remains the dominant problem and that socioeconomic factors that occur earlier in life may explain the findings. He said, "These differences are not due to inherent genetics. They are due to the effects of environmental factors like diet and exercise and obesity on biology" (Stein, Washington Post, 7/8).
Diagnostics

Regardless Of Family History, HRT-Breast Cancer Risk Stays Same

The risk of developing breast cancer due to taking hormone replacement therapy appears to be the same for women with a family history of the disease and without a family history, a University of Rochester Medical Center study concluded. The study, published online this week in the journal Epidemiology, adds to the evolving picture of what factors, either alone or in combination, boost breast cancer risk among postmenopausal women. It also refutes the notion, held by many in the medical community, that a familial predisposition to breast cancer enhances the carcinogenic effects of estrogen. "Although we know that family history is a risk factor, we don"t know yet what it is about family history that conveys the risk," said Robert E. Gramling, M.D., D.Sc., assistant professor of Family Medicine and of Community and Preventive Medicine at URMC. "Some have proposed that it might be an increased sensitivity to estrogen, but our data did not support that notion. In fact, this study suggests the causal pathway based on family history is probably not estrogen sensitivity." Researchers analyzed data from the Women"s Health Initiative randomized trial, which followed 16,608 postmenopausal women, ages 50 to 79, who took hormone replacement therapy (HRT) or a placebo pill between 1993 and 2002. Among the participants, 349 cases of invasive breast cancer occurred during a mean follow-up period of 5.6 years. Gramling divided the data into subgroups and studied the direct interaction between the contributions that the two risk factors (HRT and family history) had on breast cancer risk among postmenopausal women. The results showed only a negligible degree of interaction, suggesting that HRT conveys no greater breast cancer risk to women with, versus without, a first-degree family history of breast cancer (i.e. breast cancer in a mother, sister or daughter). The study does have limitations, the authors noted. First, the women had a short period of exposure to hormone treatment and a short follow-up period. It is possible that longer exposure to HRT would have generated different results, the study said. Also, researchers asked women about family history of breast cancer only at the start of the WHI study. Finally, the majority of women who enrolled in the WHI trial represented a more educated and somewhat healthier population, and it is unknown how this might have influenced any interaction between hormone therapy and family history. The WHI study gained notoriety when it was stopped abruptly in 2002, after data safety monitoring experts found hormonal therapy did not provide many of the benefits doctors and patients expected, and also carried some unforeseen risks. Since then, many postmenopausal women have been wary of using HRT. Scientists have continued to study the data for nuances that will lead to a more complete picture. Gramling believes his research adds a new dimension to the large body of information now available on HRT and breast cancer. "The decision to use hormonal therapy, even for a short period of time, is very difficult for many women," Gramling said. "We hope our data will provide postmenopausal women and their physicians more evidence to consider when weighing the risks versus benefits." The study was conducted using publicly available data from the WHI trial, which was supported by the National Heart Lung and Blood Institute. Leslie Orr University of Rochester Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):